In March 2022, IGH and implementing partners started conducting a nationwide serosurvey to determine the burden of disease for Hepatitis B, Hepatitis C, and COVID-19 in seven Oblasts throughout the Republic of Uzbekistan. The sample of size of the serosurvey is 15,000 participants. The data collected shows the Ministry of Health and other stakeholders the importance of treatment and prevention for infectious diseases. This has been made possible with the help of the Services for Sanitary and Epidemiological Well-being (SSEW) and the Institute of Virology (IOV).
CENTERS FOR DISEASE CONTROL AND
Participants from various Oblasts were required to register and complete a questionnaire before getting tested for Hepatitis and COVID-19. The questionnaire asks for basic medical demographic information.
IGH and CDC Uzbekistan staff members provided sample collection and data entry training to the seven participating Obalsts. These trainings allowed for the staff to asses the current capabilities for the medical staff to test and compile the testing information. Monitoring and evaluation was also a component of the survey after the initial site visit.
Medical professionals from regional polyclinics performed blood testing on the participants. The samples were then sent to the Institute of Virology to be tested.
CDC’s Deputy Chief of the Laboratory Branch at the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division, Dr. Salem Kamili visited Tashkent to share previous experience in blood collections, external quality assessments and proficiency testing programs. He provided testing demonstrations or the staff members at IOV.